Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M98,543Revenue $M18,790Net Margin (%)18.9Z-Score4.4
Enterprise Value $M107,338EPS $2.6Operating Margin %27.3F-Score6
P/E(ttm))27.4Cash Flow Per Share $0Pre-tax Margin (%)24.7Higher ROA y-yN
Price/Book21.610-y EBITDA Growth Rate %0Quick Ratio2.5Cash flow > EarningsY
Price/Sales5.15-y EBITDA Growth Rate %4.2Current Ratio2.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-14.1ROA % (ttm)12.9Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)82.0Less Shares Outstanding y-yN
Payout Ratio %71.0Shares Outstanding M1,593ROI % (ttm)22.2Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVJohn Paulson 2014-09-30 Buy 3.1%$52.05 - $59.62
($55.51)
$ 61.8511%New holding, 13000000 sh.13,000,000
ABBVAndreas Halvorsen 2014-09-30 Buy 2.5%$52.05 - $59.62
($55.51)
$ 61.8511%New holding, 10769105 sh.10,769,105
ABBVLee Ainslie 2014-09-30 Add1.26%$52.05 - $59.62
($55.51)
$ 61.8511%Add 46.01%4,723,578
ABBVSteve Mandel 2014-09-30 Buy 1.2%$52.05 - $59.62
($55.51)
$ 61.8511%New holding, 5247201 sh.5,247,201
ABBVGeorge Soros 2014-09-30 Add0.6%$52.05 - $59.62
($55.51)
$ 61.8511%Add 924.76%1,537,146
ABBVJohn Hussman 2014-09-30 Reduce-0.87%$52.05 - $59.62
($55.51)
$ 61.8511%Reduce -66.67%100,000
ABBVJoel Greenblatt 2014-09-30 Reduce-0.06%$52.05 - $59.62
($55.51)
$ 61.8511%Reduce -89.36%9,460
ABBVLee Ainslie 2014-06-30 Buy 2.6%$46.46 - $56.79
($52.4)
$ 61.8518%New holding, 3235133 sh.3,235,133
ABBVKen Fisher 2014-06-30 Add0.06%$46.46 - $56.79
($52.4)
$ 61.8518%Add 76.13%1,104,609
ABBVNWQ Managers 2014-06-30 Buy 0.05%$46.46 - $56.79
($52.4)
$ 61.8518%New holding, 83878 sh.83,878
ABBVJoel Greenblatt 2014-06-30 Reduce-0.11%$46.46 - $56.79
($52.4)
$ 61.8518%Reduce -61.19%88,923
ABBVGeorge Soros 2014-06-30 Reduce-0.1%$46.46 - $56.79
($52.4)
$ 61.8518%Reduce -57.14%150,000
ABBVJoel Greenblatt 2014-03-31 Add0.1%$46.83 - $53.68
($50.6)
$ 61.8522%Add 120.38%229,149
ABBVGeorge Soros 2014-03-31 Reduce-0.35%$46.83 - $53.68
($50.6)
$ 61.8522%Reduce -69.5%350,000
ABBVVanguard Health Care Fund 2014-03-31 Sold Out -0.28%$46.83 - $53.68
($50.59)
$ 61.8522%Sold Out0
ABBVKen Fisher 2014-03-31 Reduce-0.06%$46.83 - $53.68
($50.59)
$ 61.8522%Reduce -45.03%627,139
ABBVDavid Dreman 2014-03-31 Sold Out -0.02%$46.83 - $53.68
($50.6)
$ 61.8522%Sold Out0
ABBVDavid Dreman 2013-12-31 Buy 0.02%$44.52 - $54.32
($49.14)
$ 61.8526%New holding, 4572 sh.4,572
ABBVVanguard Health Care Fund 2013-12-31 Reduce-1.03%$44.52 - $54.32
($49.14)
$ 61.8526%Reduce -79.44%1,739,600
ABBVJohn Hussman 2013-12-31 Reduce-0.25%$44.52 - $54.32
($49.14)
$ 61.8526%Reduce -24.8%303,250
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ABBV Andreas Halvorsen 2014-09-3010,769,1050.682.5New Buy
ABBV Steve Mandel 2014-09-305,247,2010.331.2New Buy
ABBV John Paulson 2014-09-3013,000,0000.823.1New Buy
ABBV George Soros 2014-09-301,537,1460.10.66+924.76%
ABBV Lee Ainslie 2014-09-304,723,5780.34+46.01%
ABBV Dodge & Cox 2014-09-3038,84900+6%
ABBV NWQ Managers 2014-09-3085,9480.010.06+2.47%
ABBV PRIMECAP Management 2014-09-306,454,8360.410.4+2.39%
ABBV Mario Gabelli 2014-09-3010,38200
ABBV Robert Bruce 2014-09-30231,3000.013.7
ABBV Ken Fisher 2014-09-30999,7680.060.12-9.49%
ABBV John Hussman 2014-09-30100,0000.010.49-66.67%
ABBV Joel Greenblatt 2014-09-309,46000.01-89.36%
Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE WILLIAM JEVP, CFO 2014-12-22Sell8,495$68-8.88view
HURWICH THOMAS A.VP, Controller 2014-11-24Sell1,500$67.81-8.63view
GONZALEZ RICHARD AChairman of the Board and CEO 2014-03-04Sell4,799$51.221.02view
ALBAN CARLOSEVP, Commercial Operations 2014-03-03Sell2,882$50.0923.7view
CHASE WILLIAM JEVP, CFO 2014-03-03Sell3,948$50.2223.38view
SALEKI-GERHARDT AZITASVP, Operations 2014-03-03Sell2,443$50.2523.3view
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC 2014-03-03Sell4,143$50.0323.85view
RICHMOND TIMOTHY J.SVP, Human Resources 2014-02-18Sell465$51.2320.94view
RICHMOND TIMOTHY J.SVP, Human Resources 2014-02-05Sell1,460$47.7829.68view
SALEKI-GERHARDT AZITASVP, Operations 2014-02-05Sell687$47.8429.52view

Press Releases about ABBV :

    Quarterly/Annual Reports about ABBV:

    News about ABBV:

    Articles On GuruFocus.com
    Gilead Sciences Still has More Upside Jan 22 2015 
    Has Gilead Sciences Been Able To Maintain Its Lead Run In The Face Of Competition? Jan 22 2015 
    Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 
    AbbVie Inc.’s Forthcoming Future Looks Optimistic Jan 13 2015 
    Gilead Strikes Deal with CVS, Hits Back AbbVie Jan 06 2015 
    Is it Time to Sell Gilead Sciences? Dec 29 2014 
    Express Scripts Knocks Gilead’s Hepatitis C Drug in Favor of AbbVie Dec 22 2014 
    Is it Time to Sell Gilead Sciences? Dec 18 2014 
    What's More Powerful Than Compound Interest? Dec 16 2014 
    T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 

    More From Our Partners
    Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Jan 28 2015 - ZACKS

    More From Other Websites
    AmerisourceBergen's Revenue Growth May Slow Further Jan 28 2015
    HALFTIME FINAL TRADES 1/28/15 Jan 28 2015
    FMHR Final Trade: ABBV, PKI & CSX Jan 28 2015
    Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Jan 28 2015
    Can St. Jude Medical (STJ) Keep Earnings Streak Alive? - Analyst Blog Jan 27 2015
    Will Cardinal Health (CAH) Surprise Earnings This Season? - Analyst Blog Jan 27 2015
    Will PerkinElmer's (PKI) Earnings Disappoint This Season? - Analyst Blog Jan 27 2015
    Will AmerisourceBergen (ABC) Earnings Surprise in Q1? - Analyst Blog Jan 27 2015
    Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Jan 27 2015
    Varian Medical (VAR): Will Earnings Disappoint in Q1? - Analyst Blog Jan 27 2015
    Will Baxter International (BAX) Disappoint Earnings in Q4? - Analyst Blog Jan 27 2015
    Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Jan 27 2015
    AbbVie Hepatitis C Drug Will Be Focus of Profit Report --- Earnings Preview Jan 27 2015
    Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Jan 27 2015
    Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog Jan 27 2015
    Can CR Bard (BCR) Keep the Earnings Streak Alive in Q4? - Analyst Blog Jan 27 2015
    Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog Jan 27 2015
    PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary Jan 26 2015
    German insurers win discounts on Gilead's Sovaldi Jan 24 2015
    Will Accuray (ARAY) Disappoint Earnings Estimates in Q2? - Analyst Blog Jan 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK